title: Metachronous Primary Adenocarcinoma of Lung During Adjuvant Imatinib Mesylate Therapy for Gastrointestinal Stromal Tumor of Stomach: A Case Report.
abstract: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor in gastrointestinal tracts; however, the synchronous or metachronous coexistence of GIST with additional primary malignancy is not common.Here, we present an unusual case of gastric GIST with metachronous primary lung adenocarcinoma diagnosed during his adjuvant treatment with oral receptor tyrosine kinase inhibitor imatinib mesylate (400 mg daily). After 6-month use of imatinib, the patient suffered from dry cough and dyspnea. Subsequent lung biopsy demonstrated adenocarcinoma with diffuse interstitial changes.Our research emphasizes the possibility of an additional primary tumor with GIST, and reminds the clinicians to strengthen the surveillance of the additional cancer during the follow-up of GIST patients.
authors.affiliation: From the Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou (M-JJ, S-SW, YC, X-FL, YY); Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, Chinese National Ministry of Education; Key Laboratory of Molecular Biology in Medical Sciences) Zhejiang Province (M-JJ, YC, X-FL, YY); Department of Radiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou (L-HW); and Department of Pathology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou (J-HX).
authors.forename: Meng-Jie
authors.initials: MJ
authors.lastname: Jiang
authors.forename: Shan-Shan
authors.initials: SS
authors.lastname: Weng
authors.forename: Ying
authors.initials: Y
authors.lastname: Cao
authors.forename: Xiao-Fen
authors.initials: XF
authors.lastname: Li
authors.forename: Liu-Hong
authors.initials: LH
authors.lastname: Wang
authors.forename: Jing-Hong
authors.initials: JH
authors.lastname: Xu
authors.forename: Ying
authors.initials: Y
authors.lastname: Yuan
mesh_terms: D000230:Adenocarcinoma / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D000077192:Adenocarcinoma of Lung; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001706:Biopsy; D016190:Carboplatin / Q000008:administration & dosage*; D046152:Gastrointestinal Stromal Tumors / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D000068877:Imatinib Mesylate / Q000008:administration & dosage*; D033162:Incidental Findings; D008168:Lung / Q000000981:diagnostic imaging / Q000473:pathology; D008175:Lung Neoplasms / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D000068437:Pemetrexed / Q000008:administration & dosage*; D013270:Stomach / Q000473:pathology; D013274:Stomach Neoplasms / Q000150:complications / Q000175:diagnosis; D014057:Tomography, X-Ray Computed / Q000379:methods; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000068437:Pemetrexed; D000068877:Imatinib Mesylate; D016190:Carboplatin